Citigroup
VINC

Citigroup’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Citigroup’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8
Closed – – 6431
2022
Q2 		$0 Sell
8
-22
-73% -$978 ﹤0.01% 6761
2022
Q1 		$2K Sell
30
-212
-88% -$26.2K ﹤0.01% 6107
2021
Q4 		$49K Buy
242
+166
+218% +$41.4K ﹤0.01% 5076
2021
Q3 		$24K Buy
76
+65
+591% +$19K ﹤0.01% 5161
2021
Q2 		$3K Sell
11
-223
-95% -$67.9K ﹤0.01% 5942
2021
Q1 		$90K Buy
+234
New +$94.4K ﹤0.01% 4419

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Citigroup's VINC Position: Q3 2022 in Review

Citigroup sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2022, closing a stake of 8 shares.

Citigroup first reported a position in VINC in Q1 2021 and held it in 6 quarters. The position peaked at $90K in Q1 2021. 42 funds tracked by Wall St. Rank hold VINC as of Q3 2022.

  • Citigroup reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 8 Vincerx Pharma, Inc. Common Stock shares in Q3 2022.
  • Citigroup first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • Citigroup's Vincerx Pharma, Inc. Common Stock position peaked at $90K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.